MedTrace Logo

Registry of CytoSorb Therapy in COVID-19 ICU Patients

NCT04391920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2024-02-09

No results posted yet for this study

Summary

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

Conditions

Interventions

DEVICE

CytoSorb 300 mL device

CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.

Sponsors & Collaborators

  • CytoSorbents Europe GmbH

    collaborator INDUSTRY

  • CytoSorbents, Inc

    lead INDUSTRY

Principal Investigators

  • Peter Nelson, MD · CytoSorbents Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-28
Primary Completion
2022-01-20
Completion
2022-01-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391920 on ClinicalTrials.gov